HLA-antigens and life span of acute leukemia patients
Tananov, A.T.; Abakumov, E.M.
Terapevticheskii Arkhiv 53(4): 77-79
1981
ISSN/ISBN: 0040-3660 PMID: 7256647 Document Number: 174579
The occurrence of HLA antigens was studied in 200 patients with acute myelo- and lymphoblastic leukemia. In the patients with the myeloblastic leukemia, this occurrence did not differ substantially from that observed in 600 healthy subjects. In these patients, a statistically significant diminution of the occurrence of A1, B8 and B14 antigens was noted. The differences were the most distinct in groups differing in the lifespan since diagnosis. In the patients with both forms of the leukemia living for < 1 yr, A2 antigen occurrence was 25 and 28.5%, respectively, whereas in the groups of the patients with a longer lifespan, it was 88.2 and 64.7%. The occurrence of A1 antigen in both groups, and of A3 antigen in the patients with myeloblastic leukemia got much lower, as the lifespan increased. The presence of A2 antigen in patients with acute leukemia may improve the disease clinical course in most cases, while the presence of A1 and A3 antigens points to an aggravation of the pathological process.